HIV/AIDS News

Dolutegravir-based ART with two nucleoside reverse transcriptase inhibitors was superior to standard of care among children with HIV enrolled in the international ODYSSEY trial, researchers reported at CROI.

The impact of COVID-19 in pregnancy was “severe” among a cohort of HIV-positive women in South Africa, researchers reported at the Conference on Retroviruses and Opportunistic Infections.

The Conference on Retroviruses and Opportunistic Infections is being held virtually for the second year in a row because of COVID-19.

The NIH said people with HIV should be considered a high-risk group when making decisions about COVID-19 vaccine priority. The recommendation was part of the NIH’s updated interim guidance for COVID-19 and HIV.

Despite national guidelines recommending that sexually active people with HIV be tested annually for STIs, many transgender women with HIV are not tested for syphilis, chlamydia or gonorrhea, researchers reported.

According to the CDC, in 2018, Black people accounted for 13% of the United States population and 42% of the country’s new HIV diagnoses.

Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV infections among cisgender women than daily oral PrEP, according to the results of a phase 3 trial.

Dozens of African countries have made limited progress and are unlikely to meet UNAIDS targets for HIV testing and condom use by 2030, researchers reported at the HIV Research for Prevention virtual conference.

Researchers demonstrated for the first time that infusions of antibodies can prevent HIV infection.

HIV PrEP uptake has increased sixfold globally in the last 4 years but remains short of the UNAIDS target of 3 million users, according to data reported during the HIV Research for Prevention virtual conference.